Skip to content
    Real-World Studies

    Cabozantinib Starting Dose in Metastatic Renal Cell Carcinoma

    Kosola et alTherapeutic advances in urology

    Cabozantinib Starting Dose in Metastatic Renal Cell Carcinoma
    In a real-world cohort study of electronic healthcare data from the Hospital District of Southwest Finland, researchers evaluated the impact of cabozantinib monotherapy starting dose (40 mg vs 60 mg daily) on survival and safety outcomes in adults with metastatic renal cell carcinoma (mRCC) initiating treatment between March 2018 and December 2021.
    Among 71 analyzed patients, 34 (48%) received cabozantinib as first-line (1L) therapy and 37 (52%) received it as second- or later-line (2L+) treatment. Median follow-up was 16 months (interquartile range [IQR] 9.9, 23.4) for 1L and 9 months (IQR 3.6, 16.5) for 2L+. Median treatment duration reached 11 months (IQR 4.3, 15.8) in 1L and 6 months (IQR 3.0, 10.0) in 2L+. At 8 months of follow-up, 86% of 1L and 92% of 2L+ patients had not initiated a subsequent line of treatment.
    Survival analyses showed a median overall survival of 24 months in 1L and 10 months in 2L+, with no statistically significant difference identified between the 40 mg and 60 mg starting doses. However, starting at 60 mg daily in the 1L setting resulted in dose reductions or schedule modifications in 79% of patients, compared to 45% of patients who initiated therapy at 40 mg daily. Safety evaluations using CTCAE v5.0 indicated that diarrhea and hand-foot syndrome occurred more commonly than elevated liver enzymes, while grade 3 adverse events were rare. The authors concluded that survival outcomes did not show a statistically significant difference between 40 mg and 60 mg starting doses, whereas the lower starting dose was associated with fewer dose modifications and adverse events.

    Key Takeaways

    • Dose reductions or schedule modifications were required in 79% of patients initiating first-line cabozantinib at 60 mg daily compared to 45% of those starting at 40 mg daily.
    • Median overall survival was 24 months in the first-line setting and 10 months in the second- or later-line setting, with no statistically significant difference observed between the 40 mg and 60 mg starting doses.
    Read the original sourceTherapeutic advances in urology